<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38131056</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2168-9709</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The mental health clinician</Title><ISOAbbreviation>Ment Health Clin</ISOAbbreviation></Journal><ArticleTitle>Intranasal ketamine as a treatment for psychiatric complications of long COVID: A case report.</ArticleTitle><Pagination><StartPage>239</StartPage><EndPage>243</EndPage><MedlinePgn>239-243</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.9740/mhc.2023.10.239</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Neuropsychiatric symptoms associated with long COVID are a growing concern. A proposed pathophysiology is increased inflammatory mediators. There is evidence that typical serotonergic antidepressants have limited efficacy in the presence of inflammation. Although ketamine has shown promise in MDD, there is limited evidence supporting the use of ketamine to treat depressive symptoms associated with long COVID.</AbstractText><AbstractText Label="CASE REPORT" NlmCategory="UNASSIGNED">This case took place on an inpatient psychiatry unit in a Canadian hospital. The patient was admitted with a 10-month history of worsening depression and suicidality following infection with COVID-19. Depressive symptoms and suicidal ideation were assessed throughout treatment using the Montgomery-Asberg Depression Rating Scale (MADRS). Written informed consent was obtained prior to data collection. This patient received 4 doses of intranasal ketamine which resulted in rapid improvement of depressive symptoms and complete resolution of suicidality with no major adverse events.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">There is evidence to support long COVID symptoms result from dysregulated inflammatory processes. The presence of inflammation in patients with MDD has correlated to poor outcomes with first-line antidepressants. It has been demonstrated that IV ketamine is associated with decreased inflammatory mediators and proportional decrease in depressive symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Intranasal ketamine in this case was effective at treating depressive symptoms and suicidal ideation associated with long COVID. This is consistent with available data that demonstrates ketamine's efficacy in reducing inflammatory mediators associated with neuropsychiatric symptoms. Therefore, ketamine may be a potential therapeutic option to treat long COVID and persistent depressive symptoms.</AbstractText><CopyrightInformation>&#xa9; 2023 AAPP. The Mental Health Clinician is a publication of the American Association of Psychiatric Pharmacists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Kaitlyn</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5439-9123</Identifier><AffiliationInfo><Affiliation>Pharmacy Resident, University of British Columbia, Lower Mainland Pharmacy Services, Vancouver, British Columbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wanson</LastName><ForeName>Annabelle</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8920-5819</Identifier><AffiliationInfo><Affiliation>Psychiatrist and Area Department Lead (Interim), Saskatchewan Health Authority, Saskatoon, Saskatchewan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilecki</LastName><ForeName>Lee-Anne</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0001-6086-6752</Identifier><AffiliationInfo><Affiliation>Psychiatrist, Saskatchewan Health Authority, Saskatoon, Saskatchewan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalton</LastName><ForeName>Courtney</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0222-3956</Identifier><AffiliationInfo><Affiliation>Psychiatrist, Saskatchewan Health Authority, Saskatoon, Saskatchewan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Evyn</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7272-4484</Identifier><AffiliationInfo><Affiliation>Psychiatrist, Saskatchewan Health Authority, Saskatoon, Saskatchewan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halpape</LastName><ForeName>Katelyn</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6141-0439</Identifier><AffiliationInfo><Affiliation>Pharmacy Resident, University of British Columbia, Lower Mainland Pharmacy Services, Vancouver, British Columbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatrist and Area Department Lead (Interim), Saskatchewan Health Authority, Saskatoon, Saskatchewan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatrist, Saskatchewan Health Authority, Saskatoon, Saskatchewan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacist, Saskatchewan Health Authority, Saskatoon, Saskatchewan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatrist, Saskatchewan Health Authority, Saskatoon, Saskatchewan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ment Health Clin</MedlineTA><NlmUniqueID>101728585</NlmUniqueID><ISSNLinking>2168-9709</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">inflammatory mediators</Keyword><Keyword MajorTopicYN="N">ketamine</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">suicidality</Keyword></KeywordList><CoiStatement>Disclosures: K. Halpape used funding from her University of Saskatchewan College of Pharmacy and Nutrition Faculty Recruitment and Retention Program to hire Kaitlyn Baldwin as a research assistant for this work. K. Halpape has also received honoraria for work as a chapter editor for the Clinical Handbook of Psychotropic Drugs and for presentations with the Canadian Society of Hospital Pharmacists (work unrelated to this manuscript). All other authors have no disclosures to declare. This work was supported by the University of Saskatchewan College of Pharmacy and Nutrition Faculty Recruitment and Retention Program.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>22</Day><Hour>4</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38131056</ArticleId><ArticleId IdType="pmc">PMC10732124</ArticleId><ArticleId IdType="doi">10.9740/mhc.2023.10.239</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shields M, Tonmyr L, Gonzalez A, Weeks M, Park S-B, Robert A-M, et al. Symptoms of major depressive disorder during the COVID-19 pandemic: results from a representative sample of the Canadian population. Health Promot Chronic Dis Prev Can. 2021;41((11)):340&#x2013;58. doi: 10.24095/hpcdp.41.11.04.</Citation><ArticleIdList><ArticleId IdType="doi">10.24095/hpcdp.41.11.04</ArticleId><ArticleId IdType="pmc">PMC8639172</ArticleId><ArticleId IdType="pubmed">34569772</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163((1)):28&#x2013;40. doi: 10.1176/appi.ajp.163.1.28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.163.1.28</ArticleId><ArticleId IdType="pubmed">16390886</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci. 2019;73((10)):613&#x2013;27. doi: 10.1111/pcn.12902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pcn.12902</ArticleId><ArticleId IdType="pmc">PMC6851782</ArticleId><ArticleId IdType="pubmed">31215725</ArticleId></ArticleIdList></Reference><Reference><Citation>Swainson J, McGirr A, Blier P, Brietzke E, Richard-Devantoy S, Ravindran N, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force recommendations for the use of racemic ketamine in adults with major depressive disorder: recommandations du roupe De Travail Du R&#xe9;seau Canadien Pour Les Traitements De L'humeur Et De L'anxi&#xe9;t&#xe9; (Canmat) concernant l'utilisation de la k&#xe9;tamine rac&#xe9;mique chez les adultes souffrant de trouble d&#xe9;pressif majeur. Can J Psychiatry. 2021;66((2)):113&#x2013;25. doi: 10.1177/0706743720970860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0706743720970860</ArticleId><ArticleId IdType="pmc">PMC7918868</ArticleId><ArticleId IdType="pubmed">33174760</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia-Melo FS, Leal GC, Vieira F, Jesus-Nunes AP, Mello RP, Magnavita G, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord. 2020;264((3)):527&#x2013;34. doi: 10.1016/j.jad.2019.11.086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2019.11.086</ArticleId><ArticleId IdType="pubmed">31786030</ArticleId></ArticleIdList></Reference><Reference><Citation>Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet. 2016;55((9)):1059&#x2013;77. doi: 10.1007/s40262-016-0383-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-016-0383-6</ArticleId><ArticleId IdType="pubmed">27028535</ArticleId></ArticleIdList></Reference><Reference><Citation>Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175((7)):620&#x2013;30. doi: 10.1176/appi.ajp.2018.17060720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2018.17060720</ArticleId><ArticleId IdType="pubmed">29656663</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75((2)):139&#x2013;48. doi: 10.1001/jamapsychiatry.2017.3739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2017.3739</ArticleId><ArticleId IdType="pmc">PMC5838571</ArticleId><ArticleId IdType="pubmed">29282469</ArticleId></ArticleIdList></Reference><Reference><Citation>
Tibensky BN, de L&#xe9;s&#xe9;leuc L, Perras C, Picheca L.
Esketamine for treatment-resistant depression. 2019 Apr 1. 


CADTH issues in emerging health technologies. Canadian Agency for Drugs and Technologies in Health; 2016.  In. Available from:  https://www.ncbi.nlm.nih.gov/books/NBK542712/</Citation><ArticleIdList><ArticleId IdType="pubmed">31211546</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapidus KAB, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76((12)):970&#x2013;6. doi: 10.1016/j.biopsych.2014.03.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2014.03.026</ArticleId><ArticleId IdType="pmc">PMC4185009</ArticleId><ArticleId IdType="pubmed">24821196</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27((4)):601&#x2013;15. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397((10270)):220&#x2013;32. doi: 10.1016/s0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Park HY, Jung J, Park HY, Lee SH, Kim ES, Kim HB, et al. Psychological consequences of survivors of COVID-19 pneumonia 1 month after discharge. J Korean Med Sci. 2020;35((47)):e409. doi: 10.3346/jkms.2020.35.e409.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2020.35.e409</ArticleId><ArticleId IdType="pmc">PMC7721563</ArticleId><ArticleId IdType="pubmed">33289371</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236&#x2009;379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8((5)):416&#x2013;27. doi: 10.1016/s2215-0366(21)00084-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalleballe K. Onteddu S, Sharma R, Dandu V, Brown A, Jasti M, et al., editors. Spectrum of neuropsychiatric manifestations in COVID-19. Reddy. Brain Behav Immun. 2020;88((17)):71&#x2013;4. doi: 10.1016/j.bbi.2020.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.06.020</ArticleId><ArticleId IdType="pmc">PMC7297688</ArticleId><ArticleId IdType="pubmed">32561222</ArticleId></ArticleIdList></Reference><Reference><Citation>Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020;7((10)):875&#x2013;82. doi: 10.1016/s2215-0366(20)30287-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2215-0366(20)30287-x</ArticleId><ArticleId IdType="pmc">PMC7316461</ArticleId><ArticleId IdType="pubmed">32593341</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappelmann N, Dantzer R, Khandaker GM. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology. 2021;131:105295. doi: 10.1016/j.psyneuen.2021.105295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2021.105295</ArticleId><ArticleId IdType="pmc">PMC8172271</ArticleId><ArticleId IdType="pubmed">34119855</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondelli V, Pariante CM. What can neuroimmunology teach us about the symptoms of long-COVID? Oxf Open Immunol. 2021;2((1)):iqab004. doi: 10.1093/oxfimm/iqab004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfimm/iqab004</ArticleId><ArticleId IdType="pmc">PMC7928677</ArticleId><ArticleId IdType="pubmed">34192271</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, Palladini M, De Lorenzo R, Magnaghi C, Poletti S, Furlan R, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun. 2021;94:138&#x2013;47. doi: 10.1016/j.bbi.2021.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.02.021</ArticleId><ArticleId IdType="pmc">PMC7903920</ArticleId><ArticleId IdType="pubmed">33639239</ArticleId></ArticleIdList></Reference><Reference><Citation>Arteaga-Henr&#xed;quez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, Arolt V, et al. Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME consortium. Front Psychiatry. 2019;10:458. doi: 10.3389/fpsyt.2019.00458.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2019.00458</ArticleId><ArticleId IdType="pmc">PMC6630191</ArticleId><ArticleId IdType="pubmed">31354538</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan Y, Zhou Y, Zheng W, Liu W, Wang C, Lan X, et al. Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder. Transl Psychiatry. 2020;10((1)):246. doi: 10.1038/s41398-020-00933-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-020-00933-z</ArticleId><ArticleId IdType="pmc">PMC7376102</ArticleId><ArticleId IdType="pubmed">32699226</ArticleId></ArticleIdList></Reference><Reference><Citation>Meha S, Suhas S, Rao NP. Successful use of ketamine to treat severe depression with suicidality post-COVID-19 &#x2013; a case report. Psychiatry Res Case Reports. 2023;2((1)):100100. doi: 10.1016/j.psycr.2022.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psycr.2022.100100</ArticleId><ArticleId IdType="pmc">PMC9800325</ArticleId><ArticleId IdType="pubmed">36597498</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA alerts health care professionals of potential risks associated with compounded ketamine nasal spray. FDA [Internet]  2022 Feb 16 [cited 2023 Mar 26]. Available from:  https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-professionals-potential-risks-associated-compounded-ketamine-nasal-spray.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>